NASDAQ:CYAD
Delisted
Celyad SA Stock News
$0.470
+0 (+0%)
At Close: Aug 17, 2023
Information on the Total Number of Voting Rights and Shares (Articles 15 of the Law of 2 May 2007)
04:05pm, Wednesday, 20'th Jan 2021
MONT-SAINT-GUIBERT, Belgium, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
10:50am, Tuesday, 19'th Jan 2021
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium
01:00am, Monday, 18'th Jan 2021
MONT-SAINT-GUIBERT, Belgium, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology: Chance To Get In Early And Cheap
05:25pm, Thursday, 14'th Jan 2021
Celyad Oncology: Chance To Get In Early And Cheap
Celyad Oncology Appoints Marina Udier, Ph.D., to Board of Directors
04:01pm, Monday, 11'th Jan 2021
MONT-SAINT-GUIBERT, Belgium, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Announces January 2021 Conference Schedule
01:00am, Tuesday, 05'th Jan 2021
MONT-SAINT-GUIBERT, Belgium, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC
04:01pm, Tuesday, 15'th Dec 2020
MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Provides Updates on Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
01:00am, Monday, 07'th Dec 2020
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused o
Celyad Oncology Announces Dosing of First Patient in Phase 1 IMMUNICY-1 Trial of CYAD-211 for Multiple Myeloma
01:00am, Friday, 04'th Dec 2020
MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology to Participate in a Fireside Chat at the JMP Securities Hematology Summit
04:01pm, Tuesday, 01'st Dec 2020
MONT-SAINT-GUIBERT, Belgium, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Announces Third Quarter 2020 Financial Results and Recent Business Highlights
04:01pm, Tuesday, 10'th Nov 2020
MONT-SAINT-GUIBERT, Belgium, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 62nd ASH Annual Meeting and Exposition
04:01pm, Wednesday, 04'th Nov 2020
MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Announces November 2020 Investor Conference Schedule
04:01pm, Monday, 02'nd Nov 2020
MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights
08:01pm, Thursday, 06'th Aug 2020
* Interim analysis from alloSHRINK Phase 1 trial demonstrated mPFS of 3.9 months for mCRC patients with MSS disease treated with CYAD-101 following FOLFOX preconditioning; expansion cohort of alloSHRI
Celyad Oncology to Announce First Half 2020 Financial Results and Host Conference Call
05:00am, Monday, 03'rd Aug 2020
Regulatory News:
